Tech Transfer
Technology transfer at NYGC involves dedicated personnel who identify research results (e.g., patentable inventions, tangible materials, and/or copyrighted materials) which may generate potential commercial interest. Strategies are then deployed to facilitate appropriate transfer of these technologies to for-profit entities for further development which hopefully leads to commercialization. The process for transferring technologies may vary. It can involve licensing agreements or setting up joint ventures or other forms of alliances to share both the risks and rewards of bringing new technologies to market. Other corporate vehicles, e.g., spin-outs, might be used where NYGC does not have the necessary interest, resources and/or skills to develop a new technology.
Technologies Available for Licensing:
- Droplet Microfluidic Washing For High-Throughput Bioassays
- Recombinant CRISPR-Cas9 Nucleases with Altered PAM Specificity
- High-Throughput RNA-Targeting Pooled CRISPR Screens and CRISPR-Cas13 Guide Design
- Scalable Pooled CRISPR Screens with Single Cell Chromatin Accessibility Profiling
- Chemically Modified Cas13 Guides Enhance CRISPR-Cas13 RNA-Targeting Effects
If you are interested in learning more about technologies available for licensing at NYGC, contact partnering@nygenome.org.